Editas Medicine Inc (NASDAQ:EDIT) COO Alexandra Glucksmann sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, March 15th. The stock was sold at an average price of $26.41, for a total transaction of $26,410.00. Following the completion of the transaction, the chief operating officer now directly owns 118,788 shares in the company, valued at approximately $3,137,191.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Alexandra Glucksmann also recently made the following trade(s):
- On Wednesday, February 15th, Alexandra Glucksmann sold 6,000 shares of Editas Medicine stock. The stock was sold at an average price of $20.58, for a total transaction of $123,480.00.
Shares of Editas Medicine Inc (NASDAQ:EDIT) traded up 0.49% during trading on Monday, reaching $22.41. 1,434,599 shares of the company’s stock were exchanged. The company’s market capitalization is $803.17 million. The company has a 50 day moving average price of $21.84 and a 200-day moving average price of $17.26. Editas Medicine Inc has a 52-week low of $12.43 and a 52-week high of $43.50.
Editas Medicine (NASDAQ:EDIT) last released its earnings results on Friday, March 3rd. The company reported ($1.10) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.62) by $0.48. Editas Medicine had a negative return on equity of 59.22% and a negative net margin of 1,184.46%. During the same quarter last year, the business posted ($4.05) EPS. On average, equities analysts forecast that Editas Medicine Inc will post ($2.85) earnings per share for the current year.
Your IP Address:
A number of equities analysts have issued reports on EDIT shares. Zacks Investment Research cut shares of Editas Medicine from a “buy” rating to a “hold” rating in a report on Tuesday, January 10th. Jefferies Group LLC set a $35.00 target price on shares of Editas Medicine and gave the stock a “buy” rating in a report on Wednesday, January 11th. JPMorgan Chase & Co. reissued a “hold” rating on shares of Editas Medicine in a report on Sunday, February 19th. Cowen and Company reissued a “buy” rating on shares of Editas Medicine in a report on Wednesday, March 15th. Finally, Vetr raised shares of Editas Medicine from a “buy” rating to a “strong-buy” rating and set a $27.14 target price on the stock in a report on Monday. One analyst has rated the stock with a sell rating, one has issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $27.79.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. PARK CIRCLE Co purchased a new position in Editas Medicine during the third quarter worth $135,000. Russell Investments Group Ltd. purchased a new position in Editas Medicine during the fourth quarter worth $284,000. Hamilton Lane Advisors LLC purchased a new position in Editas Medicine during the third quarter worth $260,000. Victory Capital Management Inc. purchased a new position in Editas Medicine during the third quarter worth $299,000. Finally, A.R.T. Advisors LLC purchased a new position in Editas Medicine during the fourth quarter worth $417,000. 60.89% of the stock is owned by hedge funds and other institutional investors.
Editas Medicine Company Profile
Editas Medicine, Inc, formerly Gengine, Inc, is a genome editing company. The Company is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) technology.
Receive News & Ratings for Editas Medicine Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine Inc and related companies with MarketBeat.com's FREE daily email newsletter.